"We think that by dual targeting [CD19 and CD20 with KITE-363], we can decrease the antigen escape phenomena and increase immunologic pressure on the lymphoma." KITE-363 is distinguished as a dual-targeting bicistronic CAR T-cell therapy. The design of KITE-363 is intended to overcome antigen escape, which is considered a major limitation associated with current CAR T-cell therapies. Specifically, the CD20-directed CAR uses 4-1BB, while the CD19-directed CAR uses CD28. Findings emerging from the study suggest that the dual-targeting approach utilized by KITE-363 has the potential to overcome antigen escape.